-
Journal of Psychopharmacology (Oxford,... Oct 2021
Topics: Animals; Humans; Mental Disorders; Psychopharmacology; Translational Research, Biomedical
PubMed: 34634965
DOI: 10.1177/02698811211053207 -
International Clinical... Sep 2023
Topics: Humans; Psychopharmacology
PubMed: 37493237
DOI: 10.1097/YIC.0000000000000493 -
Journal of Clinical Psychopharmacology
Topics: Clinical Competence; Humans; Psychopharmacology; Psychotropic Drugs
PubMed: 34928555
DOI: 10.1097/JCP.0000000000001518 -
The World Journal of Biological... Apr 2020
Topics: Humans; Mental Disorders; Psychopharmacology
PubMed: 32478622
DOI: 10.1080/15622975.2020.1757308 -
Journal of Clinical Psychopharmacology 2019
Topics: History, 20th Century; History, 21st Century; Humans; Practice Patterns, Physicians'; Psychiatry; Psychopharmacology; Psychotropic Drugs; Switzerland
PubMed: 30516573
DOI: 10.1097/JCP.0000000000000985 -
Dialogues in Clinical Neuroscience 2019Drug development in psychiatry is gradually moving from serendipity to personalized medicine. Some promising paths will be reviewed in this issue. .
Drug development in psychiatry is gradually moving from serendipity to personalized medicine. Some promising paths will be reviewed in this issue. .
Topics: History, 20th Century; History, 21st Century; Humans; Mental Disorders; Neurosciences; Psychopharmacology
PubMed: 31636485
DOI: 10.31887/DCNS.2019.21.2/fthibaut -
Depression and Anxiety Nov 2014
Review
Topics: Humans; Mental Disorders; Neuroimaging; Pharmacogenetics; Precision Medicine; Psychopharmacology
PubMed: 25407578
DOI: 10.1002/da.22303 -
Progress in Neuro-psychopharmacology &... Jan 2011Autism spectrum disorders are characterized by impairment in social reciprocity, disturbances in language and communication, restricted interests and repetitive... (Review)
Review
Autism spectrum disorders are characterized by impairment in social reciprocity, disturbances in language and communication, restricted interests and repetitive behaviors of various types, as defined by the DSM-IV. The neurobiological bases of these disorders are poorly understood, although several abnormalities have been found. Pharmacotherapy in autism spectrum disorders lacks a solid, reliable neurobiological basis and at present it is mainly directed at the so-called associated behavioral symptoms, with limited relevance to core symptoms. Atypical neuroleptics, especially risperidone, have been shown to be useful in the treatment of behavioral symptoms in autism. Recent trials with SSRIs did not show remarkable results, in spite of their promising potential role. Attention deficit and hyperactivity disorder medications may be useful for counteracting the additional features of hyperactivity and short attention span. Antiepileptics have shown promising results but there are no specific indications for them as of yet. Research is now directed at evaluating novel treatments and combined behavioral and pharmacologic treatments, since behavioral interventions are the mainstay of the early treatment of autism. An update of currently available pharmacological treatments is provided.
Topics: Antipsychotic Agents; Autistic Disorder; Central Nervous System Agents; Clinical Trials as Topic; Humans; Psychopharmacology
PubMed: 21034789
DOI: 10.1016/j.pnpbp.2010.10.015 -
Advances in Psychosomatic Medicine 2015Despite the recent DSM-5 review of somatoform disorders, which are now called somatic symptom and related disorders, the categorical definitions of these syndromes have... (Review)
Review
Despite the recent DSM-5 review of somatoform disorders, which are now called somatic symptom and related disorders, the categorical definitions of these syndromes have inherent limitations because their causal mechanism or presumed aetiologies are still unknown. These limitations may affect everyday clinical practice and decision-making abilities. As a result, physicians have limited information at their disposal to treat these patients. Furthermore, the clinical presentations of somatic disorders may vary a lot. The purpose of this chapter is to illustrate a psychopathological dimensional approach to the somatising patient. This approach is constantly unconsciously applied in clinical practice using continuous variables, such as rating scales. Moreover, treatment strategies might be improved by adding a dimensional approach, simply recognising the prominent components of the presenting psychopathology of a given patient and addressing them with drugs according to their different mechanisms, targeting circuits and neurotransmitters. Some authors have proposed a shift from the nosological to functional application of psychotropic drugs, in which functional psychopharmacology will be dysfunction oriented and therefore inevitably geared towards utilising drug combinations. Here, we present a summary of the advantages of functional/dimensional psychopharmacology for the treatment of somatic symptoms and related disorders.
Topics: Humans; Psychopharmacology; Somatoform Disorders
PubMed: 25832511
DOI: 10.1159/000369082 -
Academic Psychiatry : the Journal of... Oct 2020
Topics: Curriculum; Hallucinogens; Humans; Internship and Residency; Psychopharmacology; Teaching
PubMed: 32860196
DOI: 10.1007/s40596-020-01294-x